- Home
- MLYS vs ARCT Comparison
MLYS vs ARCT Comparison
Compare MLYS & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- ARCT
- Stock Information
- Founded
- MLYS 2019
- ARCT 2013
- Country
- MLYS United States
- ARCT United States
- Employees
- MLYS N/A
- ARCT N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- ARCT Health Care
- Exchange
- MLYS Nasdaq
- ARCT Nasdaq
- Market Cap
- MLYS 526.1M
- ARCT 487.0M
- IPO Year
- MLYS 2023
- ARCT N/A
- Fundamental
- Price
- MLYS $10.86
- ARCT $17.65
- Analyst Decision
- MLYS Strong Buy
- ARCT Strong Buy
- Analyst Count
- MLYS 2
- ARCT 8
- Target Price
- MLYS $30.00
- ARCT $61.00
- AVG Volume (30 Days)
- MLYS 263.5K
- ARCT 405.9K
- Earning Date
- MLYS 03-20-2025
- ARCT 03-06-2025
- Dividend Yield
- MLYS N/A
- ARCT N/A
- EPS Growth
- MLYS N/A
- ARCT N/A
- EPS
- MLYS N/A
- ARCT N/A
- Revenue
- MLYS N/A
- ARCT $160,399,000.00
- Revenue This Year
- MLYS N/A
- ARCT $7.33
- Revenue Next Year
- MLYS N/A
- ARCT $4.71
- P/E Ratio
- MLYS N/A
- ARCT N/A
- Revenue Growth
- MLYS N/A
- ARCT N/A
- 52 Week Low
- MLYS $8.58
- ARCT $14.30
- 52 Week High
- MLYS $16.91
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- MLYS 51.57
- ARCT 45.85
- Support Level
- MLYS $9.81
- ARCT $15.34
- Resistance Level
- MLYS $10.79
- ARCT $17.95
- Average True Range (ATR)
- MLYS 0.62
- ARCT 1.17
- MACD
- MLYS 0.15
- ARCT -0.08
- Stochastic Oscillator
- MLYS 100.00
- ARCT 39.08
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.